328 related articles for article (PubMed ID: 31755238)
21. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Goldberg N; Fralick M
CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
[No Abstract] [Full Text] [Related]
22. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Cherney DZ; Udell JA
Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
[No Abstract] [Full Text] [Related]
23. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
24. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
25. Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.
Silva-Cardoso J; Sheikh O; Nashawi M; Pham S; Gallegos KM; Dinkha LR; Chilton RJ
J Diabetes; 2020 Apr; 12(4):279-293. PubMed ID: 31688975
[TBL] [Abstract][Full Text] [Related]
26. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
27. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Slomski A
JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528
[No Abstract] [Full Text] [Related]
28. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
29. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Inzucchi SE; Kosiborod M; Fitchett D; Wanner C; Hehnke U; Kaspers S; George JT; Zinman B
Circulation; 2018 Oct; 138(17):1904-1907. PubMed ID: 30354665
[No Abstract] [Full Text] [Related]
30. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
32. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
34. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
[No Abstract] [Full Text] [Related]
35. Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit.
Dalan R
Cardiol Rev; 2018; 26(6):312-320. PubMed ID: 29608505
[TBL] [Abstract][Full Text] [Related]
36. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
37. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Thompson J; Schacht S; Rothenberg F
Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
[TBL] [Abstract][Full Text] [Related]
38. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Jørgensen NB; Pedersen J; Vaag AA
J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
[No Abstract] [Full Text] [Related]
39. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
Raschi E; Poluzzi E; Fadini GP; Marchesini G; De Ponti F
Diabetes Obes Metab; 2018 Dec; 20(12):2711-2723. PubMed ID: 30003655
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Sattar N; McLaren J; Kristensen SL; Preiss D; McMurray JJ
Diabetologia; 2016 Jul; 59(7):1333-1339. PubMed ID: 27112340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
